Get the Stockscreener App
213.67
0.00%
-0.01
After Hours:
213.02
-0.65
-0.30%
Axsome Therapeutics Inc stock is traded at $213.67, with a volume of 476.22K.
It is down -0.00% in the last 24 hours and down -9.18% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$213.68
Open:
$211
24h Volume:
476.22K
Relative Volume:
0.56
Market Cap:
$11.19B
Revenue:
$708.24M
Net Income/Loss:
$-188.30M
P/E Ratio:
-57.14
EPS:
-3.7392
Net Cash Flow:
$-70.99M
1W Performance:
+0.44%
1M Performance:
-9.18%
6M Performance:
+17.91%
1Y Performance:
+96.48%
1-Day Range:
$208.95
$216.30
1-Week Range:
$208.95
$223.40
52-Week Range:
$108.04
$260.19
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
213.67 | 11.24B | 708.24M | -188.30M | -70.99M | -3.7392 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Initiated | Oppenheimer | Outperform |
| Apr-07-25 | Initiated | Jefferies | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
GSA Capital Partners LLP Makes New $2.31 Million Investment in Axsome Therapeutics, Inc. $AXSM - marketbeat.com
AXSM Stock Advances On CEO’s Pipeline Claim: One New Drug Filing Yearly Through 2030 - Stocktwits
AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism? - Stocktwits
AXSM Stock In Spotlight Ahead Of Key FDA Verdict On Alzheimer’s Drug This Week - Stocktwits
Axsome Therapeutics, Inc. (AXSM) Latest Stock News & Headlines - Yahoo Finance
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Raises Target Price to $316 - moomoo.com
Handelsbanken Fonder AB Has $10.38 Million Stock Position in Axsome Therapeutics, Inc. $AXSM - marketbeat.com
AXSOME THERAPEUTICS Q2 2026 Earnings Preview: Recent $AXSM Insider Trading, Hedge Fund Activity, and More - moomoo.com
AXSM|Axsome Therapeutics Inc|Price:213.630|Chg%:-1.030 - TradingKey
If You Invested $100 In Axsome Therapeutics Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Axsome Therapeutics (NASDAQ:AXSM) Faces A Crucial Test - Kalkine Media
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - simplywall.st
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Consensus Rating of "Moderate Buy" by Brokerages - marketbeat.com
AXSOME THERAPEUTICS, INC. : MIZUHO RAISES TARGET PRICE TO $316 FROM $306 - webull.com
UBS Adjusts Price Target on Axsome Therapeutics to $280 From $259, Keeps Buy Rating - moomoo.com
Mizuho raises Axsome Therapeutics stock price target on Auvelity By Investing.com - Investing.com South Africa
Mizuho raises Axsome Therapeutics stock price target on Auvelity - Investing.com
Mizuho Adjusts PT on Axsome Therapeutics to $316 From $306, Keeps Outperform Rating - marketscreener.com
Quantinno Capital Management LP Acquires 5,019 Shares of Axsome Therapeutics, Inc. $AXSM - marketbeat.com
Axsome Therapeutics Analysts Increase Their Forecasts Following Q2 Results - webull.com
Axsome Therapeutics (AXSM) Stock Faces Revenue Momentum And Lingering Losses - Sahm
AXSOME THERAPEUTICS, INC. : MORGAN STANLEY RAISES TARGET PRICE TO $251 FROM $242 - webull.com
Axsome's Q2 Earnings Meet Estimates, Auvelity Drives Y/Y Revenues - Yahoo Finance
Axsome Therapeutics (AXSM) Shares Just Climbed, So What Is Driving Attention Now? - Yahoo Finance
RBC cuts Axsome Therapeutics stock price target on model updates By Investing.com - Investing.com Australia
Axsome Therapeutics Q2 Earnings Review: I Just Can't See The Value Proposition (AXSM) - Seeking Alpha
Axsome's Auvelity Strength Expected to Drive H2 Revenue Growth, RBC Says - marketscreener.com
Axsome Therapeutics Is Maintained at Outperform by RBC Capital - moomoo.com
Wells Fargo raises Axsome Therapeutics price target to $256 By Investing.com - Investing.com Australia
RBC cuts Axsome Therapeutics stock price target on model updates - Investing.com
Needham raises Axsome Therapeutics stock price target on drug growth By Investing.com - Investing.com South Africa
AXSM Maintained by Wells Fargo -- Price Target Raised to $256 - GuruFocus
Guggenheim raises Axsome Therapeutics stock price target on sales beat By Investing.com - Investing.com Nigeria
Needham raises Axsome Therapeutics stock price target on drug growth - Investing.com
Morgan Stanley Adjusts Axsome Therapeutics PT to $251 From $242, Keeps Equalweight Rating - marketscreener.com
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $268.00 - marketbeat.com
Guggenheim raises Axsome Therapeutics stock price target on sales beat - Investing.com
Does Axsome Therapeutics (AXSM) Look Fairly Valued At This Price? - Yahoo Finance
RBC Adjusts PT on Axsome Therapeutics to $297 From $304, Maintains Outperform Rating - marketscreener.com
Faster Revenue Growth With Wider Losses Might Change The Case For Investing In Axsome (AXSM) - Sahm
Axsome Therapeutics Inc earnings missed by $0.14, revenue fell short of estimates By Investing.com - Investing.com Australia
Axsome Therapeutics, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:AXSM) 2026-08-11 - Seeking Alpha
AXSOME THERAPEUTICS Q2 OPERATING INCOME USD -49.646 MILLION - Moomoo
Axsome Therapeutics, Inc. Stock 12‑Month Price Target Raised to $282.78, Implies 33% Upside - TradingView
Axsome Therapeutics shares rise 2% despite Q2 earnings miss - Investing.com
Axsome Therapeutics 2Q 2026: Revenue $218.4M, EPS $(0.99) — 10-Q Summary - TradingView
Axsome Therapeutics (NASDAQ: AXSM) grows Q2 2026 revenue but remains unprofitable - Stock Titan
Form 8K Axsome Therapeutics Inc For: 10 August By Investing.com - Investing.com Canada
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):